Guardant Health, Inc. raised financial guidance for the full year of 2024. For the period, the company expects revenue excluding screening to be in the range of $675 to $685 million, representing growth of 20% to 21% compared to full year 2023 This compares to the prior range of $655 to $670 million, representing growth of 16% to 19%.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
25.02 USD | +11.15% | +0.08% | -6.17% |
08:06pm | Sector Update: Health Care Stocks Softer in Friday Afternoon Trading | MT |
06:49pm | Guardant Health's Shares Rise as Colorectal Cancer Detection Test Gets FDA Panel Recommendation | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.17% | 2.75B | |
-32.37% | 9.98B | |
+23.37% | 2.87B | |
-18.33% | 2.07B | |
-24.50% | 1.59B | |
+65.65% | 1.43B | |
+35.46% | 824M | |
-6.77% | 733M | |
-30.61% | 508M | |
+0.40% | 296M |
- Stock Market
- Equities
- GH Stock
- News Guardant Health, Inc.
- Guardant Health, Inc. Raises Financial Guidance for the Full Year of 2024